King Faisal Specialist Hospital, Riyadh – United Arab Emirates
About Dr. Mansour Alfayez
Dr. Mansour Alfayez is a Consultant Adult Hematologist and Acute Leukemia specialist based in Riyadh, Saudi Arabia, with US fellowship training in leukemia. A recognised acute leukemia specialist Riyadh, Saudi Arabia, he has published widely on FLT3, IDH, PTPN11 mutations, and immune checkpoint inhibitors in AML.
- US-trained adult hematologist-oncologist with a dedicated leukemia subspecialty fellowship.
- Extensive research record across acute leukemia, AML genomics, and checkpoint inhibitor therapy.
- Active participant in the Adult Leukemia Section, Hematology Department.
- Contributing author to research on FLT3, PTPN11, and CAR-T programmes in adult AML.
- Experience caring for international patients with relapsed / refractory acute leukemia.
Qualifications & Credentials
Medical Degrees
- MD (Doctor of Medicine)
- Residency — Internal Medicine, St. Elizabeth's Medical Center, Boston, USA, 2011–2014
Fellowships & Special Training
- Fellowship — Hematology and Medical Oncology, University of Texas Health Science Center at Houston / MD Anderson Cancer Center, Houston, USA, 2017–2019
- Leukemia Clinical Fellowship — University of Texas MD Anderson Cancer Center, Houston, USA
Certifications & Accreditations
- American Board of Internal Medicine (ABIM)
- ABIM — Hematology
- ABIM — Medical Oncology
- Saudi Commission for Health Specialties (SCFHS) Registration
- Member — American Society of Hematology (ASH)
- Member — American Society of Clinical Oncology (ASCO)
Areas of Expertise
Major Conditions Treated
- Acute Myeloid Leukemia (AML)
- Acute Lymphoblastic Leukemia (ALL)
- Philadelphia-Positive B-ALL
- Myelodysplastic Syndromes
- Myeloproliferative Neoplasms
- Chronic Myeloid Leukemia (CML)
- Therapy-Related Myeloid Neoplasms
- Relapsed / Refractory Acute Leukemia
- FLT3-Mutated AML
- IDH1/2-Mutated AML
Sub-specialties
- FLT3 / IDH / PTPN11-Targeted AML Therapy: Expert in molecularly targeted therapy for AML using FLT3 inhibitors (midostaurin, gilteritinib, quizartinib), IDH inhibitors, and venetoclax-based combinations — a recognised acute leukemia specialist Riyadh, Saudi Arabia.
- Immune Checkpoint Inhibitors in Leukemia: Contributor to landmark azacitidine + nivolumab / ipilimumab trials in relapsed/refractory AML, with expertise in managing immune-related adverse events.
- Ph-Positive B-ALL & Blinatumomab: Leads multi-centre retrospective reviews on blinatumomab with TKI for Philadelphia-positive B-ALL in adolescents and adults.
Advanced Procedures & Treatments
- Intensive Induction Chemotherapy for AML & ALL
- Venetoclax-Based Low-Intensity AML Regimens
- FLT3 Inhibitor Therapy (Midostaurin, Gilteritinib, Quizartinib)
- IDH1 / IDH2 Inhibitor Therapy
- Blinatumomab & Inotuzumab Ozogamicin for R/R B-ALL
- Tyrosine Kinase Inhibitor Therapy for Ph+ ALL and CML
- Immune Checkpoint Inhibitor Therapy for Leukemia
- Allogeneic HSCT Referral & Post-Transplant Management
- CAR T-cell Therapy Referral
Professional Experience
Current Affiliation
- King Faisal Specialist Hospital & Research Centre (KFSHRC), Riyadh, Saudi Arabia — Consultant, Acute Leukemia Section, Department of Hematology, Stem Cell Transplantation and Cellular Therapy (Present)
Past Affiliations
- University of Texas MD Anderson Cancer Center, Houston, USA — Leukemia Clinical Fellow
- University of Texas Health Science Center at Houston / MD Anderson Cancer Center — Fellow, Hematology and Medical Oncology, 2017–2019
- St. Elizabeth's Medical Center, Boston, USA — Internal Medicine Resident, 2011–2014
- Previously affiliated with King Fahad Medical City, Riyadh
Academic & Research Roles
- Faculty — KFSHRC Hematology Fellowship Programme
- Co-author on multi-centre AML and Ph+ ALL studies with MD Anderson Cancer Center
Key Achievements
- Extensive research record and citations across hematology and oncology
- Lead author on PTPN11-mutated AML outcomes series (single-institution 122-patient study)
- Contributor to seminal azacitidine + nivolumab ± ipilimumab R/R AML trial (Daver et al.)
- Co-author on the Saudi Acute Myeloid Leukaemia (AML) Whole-Genome Sequencing project
Awards & Recognitions
National & International Awards
- Information not publicly available.
Professional Memberships
- American Society of Hematology (ASH)
- American Society of Clinical Oncology (ASCO)
- American Board of Internal Medicine (Internal Medicine, Hematology, Medical Oncology)
- Saudi Society of Hematology
Research & Publications
Published Papers (Selected)
- Alfayez M, Issa GC, Patel KP, Wang F, Wang X, Short NJ, …, Kantarjian HM, Borthakur G. The Clinical Impact of PTPN11 Mutations in Adults with Acute Myeloid Leukemia. Leukemia / J Clin Oncol precursor papers.
- Abbas HA, Alfayez M, Kadia T, Ravandi-Kashani F, Daver N. Midostaurin in Acute Myeloid Leukemia: An Evidence-Based Review and Patient Selection. Cancer Manag Res. 2019;11:8817–8828.
- Alfaham MS, Ahmed SO, …, Alzahrani HA, Aljurf M, Rasheed W, Shaheen M, Almohareb F, Chaudhri NA, Alsharif F, Hejab A, …, Alfayez M. Saudi Acute Myeloid Leukaemia (AML) Genome Reveals Significant Differences from That in the Western Population. Blood. 2024.
Ongoing Research & Clinical Interests
- Molecular targeted therapy in FLT3 / IDH / PTPN11-mutated AML
- Immune checkpoint inhibitors in acute leukemia
- Blinatumomab / TKI combinations in Philadelphia-positive B-ALL
- Saudi Arabia AML whole-genome sequencing genomics
Estimated Treatment Costs
| Procedure / Consultation | Estimated Cost (INR) | Estimated Cost (USD) |
|---|---|---|
| Hematology Consultation | ₹1,500 – ₹3,500 | $18 – $42 |
| Bone Marrow Biopsy & Aspiration | ₹15,000 – ₹35,000 | $180 – $420 |
| Autologous Stem Cell Transplant | ₹15,00,000 – ₹22,00,000 | $18,000 – $26,500 |
| Allogeneic Stem Cell Transplant (Matched) | ₹22,00,000 – ₹35,00,000 | $26,500 – $42,000 |
| CAR T-cell Therapy | ₹1,50,00,000 – ₹3,50,00,000 | $1,80,000 – $4,20,000 |
*Indicative estimates only. Actual costs subject to hospital pricing, case complexity, and insurance. Contact Cancer Rounds for a personalised quote.
Frequently Asked Questions
1. What advanced technologies does Dr. Mansour Alfayez use in Acute Leukemia treatment?
Dr. Mansour Alfayez uses advanced acute leukemia tools including FLT3 inhibitors (midostaurin, gilteritinib, quizartinib), IDH1/IDH2 inhibitors, venetoclax-based low-intensity regimens, blinatumomab and inotuzumab ozogamicin for R/R B-ALL, TKIs for Ph+ ALL and CML, immune checkpoint inhibitors in selected AML patients, and integrated referral to allogeneic HSCT and CAR-T therapy. Cancer Rounds can coordinate virtual pre-travel consultation for international patients.
2. What conditions does Dr. Mansour Alfayez specialize in treating?
Dr. Mansour Alfayez specialises in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), Philadelphia-positive B-ALL, myelodysplastic syndromes, myeloproliferative neoplasms, chronic myeloid leukemia, therapy-related myeloid neoplasms, and FLT3- / IDH-mutated leukemia — making him a trusted acute leukemia specialist Riyadh, Saudi Arabia for best leukemia treatment and expert second opinions.
3. How do I book an appointment with Dr. Mansour Alfayez?
Appointments with Dr. Mansour Alfayez can be booked directly through the Cancer Rounds website or by contacting their international patient department for priority scheduling.
4. Can international patients receive treatment from Dr. Mansour Alfayez?
Yes. Cancer Rounds provides full assistance for international patients seeking treatment from Dr. Mansour Alfayez, including medical visa invitation letters, airport transfers, and local accommodation coordination.
5. What support is available for international patients?
International patients benefit from a dedicated concierge service provided by Cancer Rounds, including language interpretation, financial counselling, and pre-travel virtual consultations to review medical records before arrival.
6. Does Dr. Mansour Alfayez offer second opinions for Acute Leukemia cases?
Yes. Second opinion consultations with Dr. Mansour Alfayez can be arranged via Cancer Rounds for patients seeking an expert Acute Leukemia review of diagnosis, molecular risk-stratification, targeted therapy options, and allogeneic HSCT or CAR-T candidacy in Riyadh, Saudi Arabia.
